Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

NCT00410423 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Acute Leukemia
Refractory Acute Leukemia

Interventions

DRUG: Bortezomib with mitoxantrone, etoposide and cytarabine
DRUG: Bortezomib 1.0mg/m^2
DRUG: Bortezomib 1.3mg/m^2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]